       Document 0138
 DOCN  M9640138
 TI    Antibodies to LMP2A/2B in EBV-carrying malignancies.
 DT    9604
 AU    Lennette ET; Winberg G; Yadav M; Enblad G; Klein G; Virolab, Inc.,
       Berkeley, California 94710, USA.
 SO    Eur J Cancer. 1995 Oct;31A(11):1875-8. Unique Identifier : AIDSLINE
       MED/96138112
 AB    Antibodies to the Epstein-Barr virus (EBV)-encoded membrane proteins,
       LMP2A and LMP2B, were assayed in 540 individuals, including 154 patients
       with nasopharyngeal carcinoma, 16 with African Burkitt's lymphoma, 113
       with Hodgkin's disease, 14 with EBV-carrying gastric carcinoma, 14 with
       oral hairy leucoplakia (HIV+ patients), 37 with non-Hodgkin's lymphoma,
       49 with tumours of the head/neck, 19 with infectious mononucleosis, 62
       with chronic illnesses with EBV titres consistent with re-activations,
       and 62 healthy controls. A novel assay, mouse monoclonal enhanced
       indirect immunofluorescence assay (MIFA) was designed and used to test
       the sera for antibodies to the LMP2A and 2B proteins, expressed in human
       keratinocytes. Antibody to both LMP2A and LMP2B was strikingly specific
       to NPC. Virtually all (99 of 101) of the LMP2 antibody positive
       individuals were NPC patients, 95% of whom had antibodies that reacted
       both with the LMP2A- and LMP2B-transfected indicator cells, while the
       remaining 5% reacted only with the LMP2B expressing cells.
 DE    Antibodies, Viral/*BLOOD  Fluorescent Antibody Technique  Herpesviridae
       Infections/*IMMUNOLOGY  Herpesvirus 4, Human/*IMMUNOLOGY/ISOLATION &
       PURIF  Human  Keratinocytes  Nasopharyngeal
       Neoplasms/IMMUNOLOGY/VIROLOGY  Support, Non-U.S. Gov't  Tumor Virus
       Infections/*IMMUNOLOGY  Viral Matrix Proteins/*IMMUNOLOGY  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

